US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

Galecto Inc

us-stock
To Invest in {{usstockname}}
us-stock
$21.43 0.1448(14.48%) GLTO at 04 Dec 2025 04:33 PM Biotechnology
Lowest Today 18.24
Highest Today 21.94
Today’s Open 18.25
Prev. Close 19.34
52 Week High 33.60
52 Week Low 2.01
Day’s Range: Low 18.24 High 21.94
52-Week Range: Low 2.01 High 33.60
1 day return -
1 Week return +22.98
1 month return +266.27
3 month return +769.72
6 month return +563.52
1 year return +281.31
3 year return +1385.03
5 year return +49.52
10 year return -

Institutional Holdings

Novo A/S 7.54

Renaissance Technologies Corp 1.10

Susquehanna International Group, LLP 1.03

Vanguard Institutional Extnd Mkt Idx Tr 0.44

Fidelity Extended Market Index 0.39

Fidelity Total Market Index 0.19

UBS Group AG 0.17

Fidelity Series Total Market Index 0.12

Bank of America Corp 0.09

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

Tower Research Capital LLC 0.07

Vanguard U.S. Eq Idx £ Acc 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

NT Ext Eq Mkt Indx Fd DC Lend T3 0.02

NT Ext Equity Mkt Idx Fd - NL 0.02

Spartan Total Market Index Pool G 0.02

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.02

Barclays PLC 0.01

BlackRock Inc 0.01

State St US Extended Mkt Indx NL Cl C 0.01

State St US Ttl Mkt Indx NL Cl A 0.01

Northern Trust Wilshire 5000 0.00

Spartan Extended Market Index Pool F 0.00

SSgA U.S. Total Market Index Strategy 0.00

SBI Securities Co Ltd 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

Group One Trading, LP 0.00

JPMorgan Chase & Co 0.00

Morgan Stanley - Brokerage Accounts 0.00

Squarepoint Ops LLC 0.00

Market Status

Strong Buy: 1

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 30.80 M

PB Ratio 4.2477

PE Ratio 0.0

Enterprise Value 22.12 M

Total Assets 17.13 M

Volume 120649

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-45943000 -45.9M, FY22:-62041000 -62.0M, FY21:-51277000 -51.3M, FY20:-36037000 -36.0M, FY19:-38420000 -38.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-9000 -0.0M, Q1/2025:null 0.0M, Q3/2024:-60000 -0.1M, Q2/2024:-77000 -0.1M

Quarterly Net worth Q3/2025:-3133000 -3.1M, Q2/2025:-3437000 -3.4M, Q1/2025:-2533000 -2.5M, Q3/2024:-3883000 -3.9M, Q2/2024:-5338000 -5.3M

Fund house & investment objective

Company Information Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Organisation Biotechnology

Employees 5

Industry Biotechnology

CEO Dr. Hans T. Schambye M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right